转移性前列腺癌的新疗法。

New treatments for metastic prostate cancer.

出版信息

Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70.

PMID:20814400

Abstract

The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge - Dendreon) s the first immunotherapy approved for treatment of prostate cancer. Cabazitaxel (Jevtana - Sanofi-Aventis) is approved for second-line treatment of metastatic castration-resistant prostate cancer previously treated with docetaxel (Taxotere).

摘要

美国食品药品监督管理局（FDA）已批准两种用于去势抵抗性（原称激素难治性）前列腺癌的新疗法。西普列尤单抗（Provenge - Dendreon）是首个获批用于治疗前列腺癌的免疫疗法。卡巴他赛（Jevtana - 赛诺菲 - 安万特）获批用于先前接受多西他赛（泰索帝）治疗的转移性去势抵抗性前列腺癌的二线治疗。